Sign In
Buy JNJ
$239.08
+7.79 (+3.37%)
At Close: Jun 23, 2026
Texas sues J&J and Kenvue, claiming they hid Tylenol's autism risks
09:13am, Tuesday, 28'th Oct 2025
The makers of Tylenol, Johnson & Johnson and Kenvue , were sued on Tuesday by Texas Attorney General Ken Paxton, who accused them of knowingly hiding the drug's links to autism and attention deficit h
Here's Why Johnson & Johnson (JNJ) is a Strong Momentum Stock
10:50am, Monday, 27'th Oct 2025
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
JNJ vs. MRK: Which Blue-Chip Pharma Stock Should Be in Your Portfolio?
10:21am, Monday, 27'th Oct 2025
J&J's diversified growth, strong pipeline, and robust balance sheet position it as a steadier long-term pick over Merck's Keytruda-dependent outlook.
Findings highlight opportunity for shared decision-making to improve treatment planning, with more than 90% of patients currently on injectables willing to switch to a new oral therapy with equivalent
Building on 12-week findings, icotrokinra demonstrated clinically meaningful outcomes at Week 28 with 31.7% of patients achieving clinical remission and 38.1% showing endoscopic improvement versus pla
Clinical remission rates were over 85% for both TREMFYA® maintenance doses at 96 weeks in both the Phase 3 GRAVITI and GALAXI studies TREMFYA® is the only IL-23 inhibitor to demonstrate durable endo
Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS study with statistically significant improvement in ClinESSDAI score , which is
I have invested in dividends for 25 years—These stocks prove long-term dividend investing works
11:29am, Friday, 24'th Oct 2025
McDonald's (MCD), Johnson & Johnson (JNJ), and Walmart (WMT) have lengthy histories of dividend growth. Sticking to a dividend reinvestment plan with these three stocks yielded amazing results over th
In areas of high impact, 72% of patients with scalp psoriasis and 85% with genital psoriasis treated with icotrokinra achieved site-specific clear or almost clear skin at Week 52 in Phase 3 ICONIC-TOT
Smart Acquisitions And Profit Margin Growth Amid Strategic Repositioning
04:30am, Friday, 24'th Oct 2025
We purchased several new fund holdings across various sectors. Sempra has been shifting its strategic focus from its highly regulated California operations to its growing presence in Texas. Regeneron
I have invested in dividends for 20 years. These stocks are my top dividend compounders of all time
11:26am, Thursday, 23'rd Oct 2025
In the world of investing, dividends have long been a popular way to earn income alongside growth opportunities with stocks.
Johnson & Johnson to Participate in the 7th Annual Wolfe Research Healthcare Conference
04:36pm, Wednesday, 22'nd Oct 2025
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the 7th Annual Wolfe Research Healthcare Conference on Monday, November 17th, 2025. Management will participate in a
Johnson & Johnson Stock To $134?
02:00pm, Wednesday, 22'nd Oct 2025
Our machine-driven multifactor analysis suggests it may be time to sell JNJ stock, as we hold a pessimistic outlook with a potential target price of $134. The company's Moderate operating performance
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
10:00am, Wednesday, 22'nd Oct 2025
Johnson & Johnson (JNJ) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Johnson & Johnson Draws Long-Term Buyers as Markets Turn Cautious
04:49pm, Tuesday, 21'st Oct 2025
Added 91,615 shares in Johnson & Johnson; estimated transaction value of ~$15.70 million Trade represents an increase of 2.13% of the fund's reportable U.S. equity AUM Post-trade stake: 102,375 shares
